Ticker Details
Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes.
IPO Date:	February 3, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$174.74M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.68 | 3.39%
Avg Daily Range (30 D):	$0.08 | 4.00%
Avg Daily Range (90 D):	$0.09 | 3.56%

Institutional Daily Volume
Avg Daily Volume:	1.32M
Avg Daily Volume (30 D):	1.61M
Avg Daily Volume (90 D):	1.82M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	228
Avg Trade Size (Sh.) (90 D):	196

Institutional Trades
Total Institutional Trades:	3,813
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$2.07M
Avg Institutional Trade (90 D):	$1.51M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.78M
Avg Closing Trade (30 D):	$2.07M
Avg Closing Trade (90 D):	$1.99M
Avg Closing Volume:	160.13K

News

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Nov 17, 2025 @ 3:00 PM Gene Therapies for Cancer Treatment Market Project... Source: Towards Healthcare

Sep 25, 2025 @ 1:15 PM Healthcare Innovation Accelerates as Four Convergi... Source: Prnewswire

Sep 2, 2025 @ 10:00 AM Gene Editing Market to Surpass USD 15.46 Billion b... Source: Sns Insider

Jun 27, 2025 @ 12:15 PM 2 Beaten-Down Stocks to Avoid Source: Prosper Junior Bakiny

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-2.37	$-.28	$-.63
Diluted EPS	$-2.37	$-.28	$-.63
Revenue	$46.38M	$7.54M	$3.58M
Gross Profit
Net Income / Loss	$-199.84M	$-25.12M	$-53.24M
Operating Income / Loss	$-198.85M	$-24.55M	$-51.54M
Cost of Revenue
Net Cash Flow	$68.61M	$25.9M	$-.15M
PE Ratio